{"id":1168,"date":"2024-03-14T15:31:53","date_gmt":"2024-03-14T15:31:53","guid":{"rendered":"https:\/\/newsletters.aans.org\/tumor\/?page_id=1168"},"modified":"2024-03-28T14:54:46","modified_gmt":"2024-03-28T14:54:46","slug":"clinical-trials-and-registries","status":"publish","type":"page","link":"https:\/\/newsletters.aans.org\/tumor\/spring-2024\/clinical-trials-and-registries\/","title":{"rendered":"Clinical Trials and Registries"},"content":{"rendered":"

Co-Chairs<\/strong>: Brad Elder, MD, and Gavin Dunn, MD\"\"\"\"
\nMembers:<\/strong>\u00a0Dan Cahill, MD, Melanie Hayden Gephart, MD,\u00a0Mark Linskey, MD, Timothy Smith, MD, Andrew Sloan, MD, and\u00a0Michael Vogelbaum, MD<\/p>\n

From the \u201cClinical Trials and Registries\u201d Committee, we are excited to provide updates on important tumor registries and highlight clinical trial activity. In addition to this update, we are planning to send a survey to neurosurgeons who specialize in neurosurgical oncology. This survey aims to gauge involvement and interest in national clinical trials and tumor outcomes registries. The survey should be brief, and we are targeting the maximal engagement of our peers. Please look for this survey in your email in the coming months.<\/p>\n

Clinical Trials in Neuro-Oncology<\/em><\/p>\n

Important dates:
\nNRG Winter Meeting: Orlando, Fla., February 15-17, 2024
\nAlliance Spring Meeting: Chicago, Ill. (hybrid meeting), May 15-18, 2024
\nNRG: Denver, Colo., July 25-27, 2024
\nAlliance Fall Meeting: Chicago, Ill. (hybrid meeting), October 30 \u2013 November 2, 2024<\/p>\n

In the Fall 2023 Report, we highlighted the NRG study NRG-BN012, \u201cA randomized phase III trial of pre-operative compared to post-operative stereotactic radiosurgery in patients with resectable brain metastases\u201d.<\/p>\n

In this report, we highlight the Alliance trial \u201cA071401, Phase II Trial of SMO\/ AKT\/ NF2\/CDK Inhibitors in Progressive Meningiomas with SMO\/ AKT\/ NF2\/CDK Pathway Mutations.\u201d Inclusion criteria are patients with progressive meningiomas harboring SMO, AKT, NF2 or CDK pathway mutations. The primary objective is to determine the activity of inhibitors matched to each of the four mutation pathways. This includes vismodegib (SMO\/PTCH1 mutation), FAK inhibitor GSK2256098 (NF2 mutation), capivasertib (AKT1, PIK3CA or PTEN mutation) and abemaciclib (CDK4, CDK6, CDKN2A, CCND1, CCND2, CCND3, CCNE1 mutation). Target enrollment is 124 patients. PI is Priscilla Brastianos, MD.<\/p>\n

Further information regarding this clinical trial can be obtained from the NeuroPoint Alliance website at or clinicaltrials.gov.<\/p>\n

NeuroPoint Alliance <\/em><\/p>\n

Background:<\/p>\n

The NeuroPoint Alliance (NPA) was established in 2008 to improve quality of care for neurosurgical patients through acquisition and analysis of clinical outcomes data. The goals of the NPA include:<\/p>\n